EMERALD Subgroup Analysis in HER2-Low Metastatic Breast Cancer: Safety and Efficacy of Elacestrant

In separate, virtual live events, Sarah Sammons, MD, and Ruth O’Regan, MD, discussed molecular profiling and therapeutic options for a patient with advanced breast cancer after multiple lines of therapy.

In season 3, episode 3 of Targeted Talks, William J. Gradishar, MD, discusses the latest version of the NCCN Clinical Practice Guideline for managing early-stage breast cancer.

Trastuzumab deruxtecan therapy led to superior PFS vs chemotherapy in pretreated, HR-positive, HER2-low metastatic breast cancer as well as ‘ultralow’ disease with IHC 0 and membrane staining.

In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.

Progression-free survival was numerically improved with pembrolizumab plus sacituzumab govitecan vs sacituzumab govitecan alone in patients with HR-positive, HER2-negative metastatic breast cancer.

Data from the phase 3 INAVO120 trial support the priority review granted by the FDA to inavolisib, palbociclib, and fulvestrant for the treatment of PIK3CA-mutated breast cancer.